<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="47279"><DrugName>ProQuad</DrugName><DrugNamesKey><Name id="42807256">ProQuad</Name></DrugNamesKey><DrugSynonyms><Name><Value>ProQuad</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>MMR(II)V, Merck &amp; Co</Value></Name><Name><Value>MMR-V, Aventis Pasteur MSD</Value></Name><Name><Value>MMR-V, Aventis Pasteur/Merck &amp; Co</Value></Name><Name><Value>measles, mumps, rubella, varicella vaccine, Aventis Pasteur MSD</Value></Name><Name><Value>measles, mumps, rubella, chickenpox vaccine, Aventis Pasteur MSD</Value></Name><Name><Value>measles, mumps, rubella, rubella vaccine, Aventis Pasteur/Merck &amp; Co</Value></Name><Name><Value>measles, mumps, rubella, varicella vaccine, sanofi-aventis/Merck &amp; Co</Value></Name><Name><Value>MMR-V vaccine, Merck &amp; Co/sanofi-aventis</Value></Name><Name><Value>measles, mumps, rubella, chickenpox vaccine, sanofi pasteur MSD</Value></Name><Name><Value>measles, mumps, rubella, varicella vaccine, sanofi pasteur/Merck &amp; Co</Value></Name><Name><Value>measles, mumps, rubella, varicella vaccine, sanofi pasteur MSD</Value></Name><Name><Value>MMR-V, sanofi pasteur/Merck &amp; Co</Value></Name><Name><Value>MMR-V, sanofi pasteur MSD</Value></Name><Name><Value>MMR II + Varivax, sanofi pasteur MSD</Value></Name><Name><Value>V-221</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18077">Merck &amp; Co Inc</CompanyOriginator><CompaniesPrimary><Company id="18077">Merck &amp; Co Inc</Company><Company id="1113858">Seqirus</Company></CompaniesPrimary><CompaniesSecondary><Company id="1083827">bioCSL PTY Ltd</Company><Company id="23408">Sanofi Pasteur MSD</Company></CompaniesSecondary><CrossReferences><SourceEntity id="47279" type="Drug"><TargetEntity id="358940" type="siDrug">ProQuad</TargetEntity></SourceEntity><SourceEntity id="1083827" type="Company"><TargetEntity id="5039880217" type="organizationId">Seqirus Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="1113858" type="Company"><TargetEntity id="5050924021" type="organizationId">Seqirus Inc</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="23408" type="Company"><TargetEntity id="4296729711" type="organizationId">MSD Vaccins SAS</TargetEntity></SourceEntity><SourceEntity id="1" type="ciIndication"><TargetEntity id="B05" type="ICD10"></TargetEntity><TargetEntity id="055" type="ICD9"></TargetEntity><TargetEntity id="10027011" type="MEDDRA"></TargetEntity><TargetEntity id="D008457" type="MeSH"></TargetEntity><TargetEntity id="-145534850" type="omicsDisease"></TargetEntity><TargetEntity id="1716" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="392" type="ciIndication"><TargetEntity id="10046980" type="MEDDRA"></TargetEntity><TargetEntity id="D006562" type="MeSH"></TargetEntity><TargetEntity id="-139769662" type="omicsDisease"></TargetEntity><TargetEntity id="859" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="449" type="ciIndication"><TargetEntity id="B26" type="ICD10"></TargetEntity><TargetEntity id="10028257" type="MEDDRA"></TargetEntity><TargetEntity id="D009107" type="MeSH"></TargetEntity><TargetEntity id="-174365253" type="omicsDisease"></TargetEntity><TargetEntity id="3084" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="460" type="ciIndication"><TargetEntity id="B06" type="ICD10"></TargetEntity><TargetEntity id="10039252" type="MEDDRA"></TargetEntity><TargetEntity id="D012409" type="MeSH"></TargetEntity><TargetEntity id="-1167536322" type="omicsDisease"></TargetEntity><TargetEntity id="2378" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Measles virus infection - US - Sep-2005</FirstLaunched><FirstLaunched>Mumps virus infection - US - Sep-2005</FirstLaunched><FirstLaunched>Rubella virus infection - US - Sep-2005</FirstLaunched><FirstLaunched>Varicella zoster virus infection - US - Sep-2005</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1">Measles virus infection</Indication><Indication id="392">Varicella zoster virus infection</Indication><Indication id="449">Mumps virus infection</Indication><Indication id="460">Rubella virus infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12364">Live attenuated viral vaccine</Action><Action id="12375">Toxoid vaccine</Action><Action id="12378">Prophylactic vaccine</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="745">Suspension</Technology><Technology id="750">Freeze drying</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-06-20T10:32:57.000Z</LastModificationDate><ChangeDateLast>2018-04-09T00:00:00.000Z</ChangeDateLast><AddedDate>2003-10-21T12:54:33.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23408" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;, previously through its joint venture with  &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;,  &lt;ulink linkID="23408" linkType="Company"&gt;Sanofi Pasteur MSD&lt;/ulink&gt;), has developed and launched  ProQuad (MMR-V; V-221), a combination vaccine consisting of &lt;ulink linkID="3643" linkType="Drug"&gt;MMR-II&lt;/ulink&gt; (Measles, Mumps, Rubella Virus Vaccine Live) and &lt;ulink linkID="4645" linkType="Drug"&gt;Varivax&lt;/ulink&gt;. The product is indicated for active immunization for the prevention of measles, mumps, rubella and chicken pox in children aged 12 months to 12 years old [&lt;ulink linkID="1161203" linkType="Reference"&gt;1161203&lt;/ulink&gt;], [&lt;ulink linkID="1889108" linkType="Reference"&gt;1889108&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, the US launch of ProQuad took place; EU launch took place in April 2006 [&lt;ulink linkID="647805" linkType="Reference"&gt;647805&lt;/ulink&gt;], [&lt;ulink linkID="915414" linkType="Reference"&gt;915414&lt;/ulink&gt;]. In March 2012, the EMA's CHMP recommended a variation to the ProQuad MAA, allowing use for individuals from 9 months of age under special circumstances [&lt;ulink linkID="1272434" linkType="Reference"&gt;1272434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, the FDA approved an sBLA for frozen and refrigerator-stable formulations of ProQuad in the US [&lt;ulink linkID="1540818" linkType="Reference"&gt;1540818&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;According to TS patent analysts, several patent applications, if granted, may provide ProQuad with patent protection. The application WO-09962500 was pending in the US as of January 2006, and covered ProQuad with rHA and hydrolyzed gelatin stabilizers, and sorbitol and sucrose in addition to other pH modifiers that match the ProQuad product description. This application was a continuation of earlier US granted patents, so if the US equivalent was granted it would have expired on December 18, 2007. Another possibility, which covers the quad vaccine, although without the stated stabilizers, is &lt;ulink linkID="IN1488175" linkType="Patent"&gt;US-05024836&lt;/ulink&gt;, which expired October 19, 2009. &lt;ulink linkID="PA3106749" linkType="Patent"&gt;US-06210683&lt;/ulink&gt;, a third example, lapsed in 2005 due to non-payment of fees, suggesting that Merck did not believe this patent offered sufficient protection to ProQuad [&lt;ulink linkID="645283" linkType="Reference"&gt;645283&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2004, a BLA was filed with the FDA, and notification of acceptance was received in November 2004 [&lt;ulink linkID="569055" linkType="Reference"&gt;569055&lt;/ulink&gt;]. The FDA approved the vaccine in September 2005 and launch took place later that month [&lt;ulink linkID="621581" linkType="Reference"&gt;621581&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, an sBLA was approved in the US for frozen and refrigerator-stable formulations of ProQuad [&lt;ulink linkID="1540818" linkType="Reference"&gt;1540818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2004, EMEA review was initiated and in September 2005, the CHMP recommended the approval of ProQuad [&lt;ulink linkID="623472" linkType="Reference"&gt;623472&lt;/ulink&gt;]. In March 2006, the product was approved in France [&lt;ulink linkID="1350755" linkType="Reference"&gt;1350755&lt;/ulink&gt;].  In April 2006, it was launched in EU [&lt;ulink linkID="915414" linkType="Reference"&gt;915414&lt;/ulink&gt;]. In March 2012, the EMA's CHMP recommended a variation to the MAA, allowing ProQuad use for individuals from 9 months of age under special circumstances (such as to conform with national vaccination schedules, outbreak situations, or travel to a region with high  prevalence of measles) [&lt;ulink linkID="1272434" linkType="Reference"&gt;1272434&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By January 2008, the vaccine had been approved in Korea [&lt;ulink linkID="946712" linkType="Reference"&gt;946712&lt;/ulink&gt;]. It was presumed that the combination was made available shortly after, as MMR-II and  Varivax were already launched in Korea.&lt;/para&gt;&lt;para&gt;In February 2007, the drug was approved by the Australian Therapeutic Goods Administration [&lt;ulink linkID="1700578" linkType="Reference"&gt;1700578&lt;/ulink&gt;]. By August 2013, the drug was being marketed by &lt;ulink linkID="1083827" linkType="Company"&gt;BioCSL&lt;/ulink&gt; (now &lt;ulink linkID="1113858" linkType="Company"&gt;Seqirus&lt;/ulink&gt;) in Australia [&lt;ulink linkID="1478930" linkType="Reference"&gt;1478930&lt;/ulink&gt;], [&lt;ulink linkID="1735777" linkType="Reference"&gt;1735777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Safety Information&lt;/subtitle&gt;The FDA approved a revised label in February 2008, warning of an increased risk of febrile seizures [&lt;ulink linkID="1156557" linkType="Reference"&gt;1156557&lt;/ulink&gt;]. In April 2014, the FDA approved an sBLA to include the term acute disseminated encephalomyelitits in the label for the frozen and refrigerator-stable formulations of ProQuad [&lt;ulink linkID="1551033" linkType="Reference"&gt;1551033&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;A post-licensure retrospective cohort study was undertaken to assess the incidence of febrile convulsion following ProQuad vaccination, and data were published in July 2009. During the 30 days post-vaccination, there were 128 potential case of convulsion in 31,298 children vaccinated with ProQuad, compared to 94 potential cases in children who received concommitant MMR and varicella vaccination, suggesting the risk of febrile convulsion is increased with ProQuad [&lt;ulink linkID="1161217" linkType="Reference"&gt;1161217&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2007, an open-label, randomized, comparative, multi-centre phase III study (&lt;ulink linkID="11632" linkType="Protocol"&gt;NCT00566527&lt;/ulink&gt;; V221-038; MRV02C) was initiated in healthy children (n = 1260) in Finland, France and Germany, to evaluate the immunogenicity and safety of a 2-dose regimen of ProQuad manufactured with recombinant human albumine. In December 2008, the trial was completed [&lt;ulink linkID="1925715" linkType="Reference"&gt;1925715&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2007, an open-label, non-randomized, multicenter, phase III trial (&lt;ulink linkID="11426" linkType="Protocol"&gt;NCT00560755&lt;/ulink&gt;; V221-037, MRV01C, MCMVaccBV) began to evaluate  safety profile and prevention in pediatric patients (n =  3340)  with  measles, mumps, rubella and varicella virus infection in Europe. In November 2008, the trial was completed [&lt;ulink linkID="1915258" linkType="Reference"&gt;1915258&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, Merck presented clinical data at the National Immunization Conference in Nashville, TN, showing that a single injection of ProQuad in previously-vaccinated young children resulted in antibody responses similar to those seen in children given the &lt;ulink linkID="3643" linkType="Drug"&gt;MMR II&lt;/ulink&gt; and &lt;ulink linkID="4645" linkType="Drug"&gt;Varivax&lt;/ulink&gt; vaccines. In the double-blind, multicenter study, 799 healthy children of 4 to 6 years of age who previously received MMR II and &lt;ulink linkID="4645" linkType="Drug"&gt;Varivax&lt;/ulink&gt; at 12 months or older were randomized to receive ProQuad and placebo, MMR II and placebo or MMR II and Varivax concomitantly at separate injection sites. Participants who received ProQuad with placebo as a second dose achieved antibody levels to measles, mumps and rubella that were similar to levels seen in the groups receiving MMR II and placebo and MMR II and Varivax concomitantly when measured at 6 weeks after vaccination. ProQuad was also well tolerated [&lt;ulink linkID="538552" linkType="Reference"&gt;538552&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1997, results were published from a study comparing responses to ProQuad or &lt;ulink linkID="3643" linkType="Drug"&gt;MMR II&lt;/ulink&gt; plus &lt;ulink linkID="4645" linkType="Drug"&gt;Varivax&lt;/ulink&gt; in 812 children aged 1 to 3.5 years. Over 95% of children seroconverted for each virus, but anti-varicella antibody titers were lower in the ProQuad group than in the Varivax group [&lt;ulink linkID="273292" linkType="Reference"&gt;273292&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1996, results were published from a study in which 165 healthy children between 12 and 19 months were administered ProQuad or an MMR vaccine plus a varicella vaccine. All children seroconverted to all viruses. The vaccines were well tolerated [&lt;ulink linkID="509697" linkType="Reference"&gt;509697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1995, results were published from a clinical trial in which 150 children with and without respiratory tract infections (RTIs) were administered ProQuad sc. Seroconversion to measles, mumps and rubella antibodies occurred in all children. Seroconversion to varicella occurred in all healthy children and in 96% of children with RTIs [&lt;ulink linkID="509724" linkType="Reference"&gt;509724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1986, results were published from a clinical trial in which 25 children between 15 and 18 months received ProQuad or a standard MMR vaccine then a varicella vaccine 6 weeks later. The vaccines were provided by &lt;ulink linkID="18077" linkType="Company"&gt;Merck&lt;/ulink&gt;, Sharp &amp;amp; Dohme. All children seroconverted and ProQuad showed equivalency to the MMR plus varicella vaccination regimen [&lt;ulink linkID="511970" linkType="Reference"&gt;511970&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2005, ProQuad was made available in the US Center for Disease Control's (CDC) Vaccine for Children (VFC) program. The VFC initiative provided the vaccine to Medicaid-eligible, uninsured and Native American children [&lt;ulink linkID="647805" linkType="Reference"&gt;647805&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1113858">Seqirus</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate><Source id="1735777" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1113858">Seqirus</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate><Source id="1735777" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1113858">Seqirus</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate><Source id="1735777" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1113858">Seqirus</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate><Source id="1735777" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-01T00:00:00.000Z</StatusDate><Source id="1889108" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-08T00:00:00.000Z</StatusDate><Source id="1700578" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-08T00:00:00.000Z</StatusDate><Source id="1700578" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-08T00:00:00.000Z</StatusDate><Source id="1700578" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-08T00:00:00.000Z</StatusDate><Source id="1700578" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-06T00:00:00.000Z</StatusDate><Source id="1350755" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-06T00:00:00.000Z</StatusDate><Source id="1350755" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-06T00:00:00.000Z</StatusDate><Source id="1350755" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-06T00:00:00.000Z</StatusDate><Source id="1350755" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-01T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="647805" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="647805" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="647805" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="647805" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="915414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="915414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="915414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="915414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-01T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-01T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-01T00:00:00.000Z</StatusDate><Source id="946712" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083827">bioCSL PTY Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-19T00:00:00.000Z</StatusDate><Source id="1478930" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083827">bioCSL PTY Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-19T00:00:00.000Z</StatusDate><Source id="1478930" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083827">bioCSL PTY Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-19T00:00:00.000Z</StatusDate><Source id="1478930" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083827">bioCSL PTY Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-19T00:00:00.000Z</StatusDate><Source id="1478930" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-12-31T00:00:00.000Z</StatusDate><Source id="511970" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-12-31T00:00:00.000Z</StatusDate><Source id="511970" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-12-31T00:00:00.000Z</StatusDate><Source id="511970" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-12-31T00:00:00.000Z</StatusDate><Source id="511970" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-08-31T00:00:00.000Z</StatusDate><Source id="569057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-08-31T00:00:00.000Z</StatusDate><Source id="569057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-08-31T00:00:00.000Z</StatusDate><Source id="569057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-08-31T00:00:00.000Z</StatusDate><Source id="569057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="569057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-26T00:00:00.000Z</StatusDate><Source id="509200" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-06T00:00:00.000Z</StatusDate><Source id="621581" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-06T00:00:00.000Z</StatusDate><Source id="621581" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-06T00:00:00.000Z</StatusDate><Source id="621581" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-06T00:00:00.000Z</StatusDate><Source id="621581" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1">Measles virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-18T00:00:00.000Z</StatusDate><Source id="623472" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="392">Varicella zoster virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-18T00:00:00.000Z</StatusDate><Source id="623472" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="449">Mumps virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-18T00:00:00.000Z</StatusDate><Source id="623472" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="460">Rubella virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-18T00:00:00.000Z</StatusDate><Source id="623472" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2125640" linkType="reference" linkID="2125640"&gt;2125640&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2116146" linkType="reference" linkID="2116146"&gt;2116146&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15563">CSL Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="28965">Novozymes A/S</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="120578" title="Merck &amp; Co and Pasteur Mérieux Connaught to develop and market vaccines in Europe via their Aventis Pasteur MSD joint venture             "></Deal><Deal id="156598" title="bioCSL to market Merck's ProQuad vaccine against measles, mumps and rubella Varicella zoster virus infections in Australia          "></Deal><Deal id="245543" title="Albumedix and Merck to develop Proquad for varicella virus infectuion and M-M-R-II for measles,mumps and rubella virus infection using recombumin technology"></Deal></Deals><PatentFamilies><PatentFamily id="1018721" number="US-03985615" title="Process for preparing live-varicella vaccines"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osaka University" id="20653"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>